A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 10.1 EUR Market Closed
Market Cap: 85.9m EUR
Have any thoughts about
Apontis Pharma AG?
Write Note

Apontis Pharma AG
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Apontis Pharma AG
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Apontis Pharma AG
XETRA:APPH
Revenue
€37m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Revenue
$314k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Revenue
€46.7B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
1%
Merck KGaA
XETRA:MRK
Revenue
€21B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
7%
Dermapharm Holding SE
XETRA:DMP
Revenue
€1.2B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Revenue
€101.1m
CAGR 3-Years
17%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

Apontis Pharma AG
Glance View

Market Cap
84.1m EUR
Industry
Pharmaceuticals

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.

APPH Intrinsic Value
17.03 EUR
Undervaluation 41%
Intrinsic Value
Price
A

See Also

What is Apontis Pharma AG's Revenue?
Revenue
37m EUR

Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Revenue amounts to 37m EUR.

What is Apontis Pharma AG's Revenue growth rate?
Revenue CAGR 3Y
-2%

Over the last year, the Revenue growth was -34%. The average annual Revenue growth rates for Apontis Pharma AG have been -2% over the past three years .

Back to Top